{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:15:10Z","timestamp":1790745310869,"version":"4.1.0"},"reference-count":193,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T00:00:00Z","timestamp":1623974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Regione Toscana Bando Salute 2018","award":["D78D20000870002"],"award-info":[{"award-number":["D78D20000870002"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Soft tissue sarcomas (STSs) are a heterogeneous group of rare tumors. Although constituting only 1% of all human malignancies, STSs represent the second most common type of solid tumors in children and adolescents and comprise an important group of secondary malignancies. Over 100 histologic subtypes have been characterized to date (occurring predominantly in the trunk, extremity, and retroperitoneum), and many more are being discovered due to molecular profiling. STS mortality remains high, despite adjuvant chemotherapy. New prognostic stratification markers are needed to help identify patients at risk of recurrence and possibly apply more intensive or novel treatments. Recent scientific advancements have enabled a more precise molecular characterization of sarcoma subtypes and revealed novel therapeutic targets and prognostic\/predictive biomarkers. This review aims at providing a comprehensive overview of the most relevant cellular, molecular and metabolic biomarkers for STS, and highlight advances in STS-related biomarker research.<\/jats:p>","DOI":"10.3390\/cancers13123044","type":"journal-article","created":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T11:19:20Z","timestamp":1624015160000},"page":"3044","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Soft Tissue Sarcoma: An Insight on Biomarkers at Molecular, Metabolic and Cellular Level"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8861-8718","authenticated-orcid":false,"given":"Serena","family":"Pillozzi","sequence":"first","affiliation":[{"name":"Medical Oncology Unit, Careggi University Hospital, Largo Brambilla 3, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bernini","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9366-0574","authenticated-orcid":false,"given":"Ilaria","family":"Palchetti","sequence":"additional","affiliation":[{"name":"Department of Chemistry Ugo Schiff, University of Florence, Via della Lastruccia 3, 50019 Sesto Fiorentino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Crociani","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla 3, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Antonuzzo","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Careggi University Hospital, Largo Brambilla 3, 50134 Florence, Italy"},{"name":"Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla 3, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3912-3943","authenticated-orcid":false,"given":"Domenico","family":"Campanacci","sequence":"additional","affiliation":[{"name":"Department of Health Science, University of Florence, Largo Brambilla 3, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Scoccianti","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Oncology and Reconstructive Surgery, University of Florence, Careggi University Hospital, Largo Brambilla 3, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,18]]},"reference":[{"key":"ref_1","unstructured":"International Agency for Research on Cancer (2020). WHO Classification of Tumours Editorial Board. Soft Tissue and Bone Tumours."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/PAP.0000000000000284","article-title":"The 2020 WHO Classification of Tumors of Soft Tissue: Selected Changes and New Entities","volume":"28","author":"Choi","year":"2021","journal-title":"Adv. Anat. Pathol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.canep.2019.02.012","article-title":"Soft tissue sarcoma in Italy: From epidemiological data to clinical networking to improve patient care and outcomes","volume":"59","author":"Trama","year":"2019","journal-title":"Cancer Epidemiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/pbc.23252","article-title":"Soft tissue sarcoma across the age spectrum: A population-based study from the Surveillance Epidemiology and End Results database","volume":"57","author":"Ferrari","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/annonc\/mdz124","article-title":"Surgery in reference centers improves survival of sarcoma patients: A nationwide study","volume":"30","author":"Blay","year":"2019","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/jnci\/djk002","article-title":"Risk of Soft Tissue Sarcomas by Individual Subtype in Survivors of Hereditary Retinoblastoma","volume":"99","author":"Kleinerman","year":"2007","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijrobp.2018.09.028","article-title":"Patterns of Care and Outcome Radiation-Induced Soft Tissue Sarcomas","volume":"103","author":"Italiano","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1056\/NEJM199501053320103","article-title":"Association of Epstein-Barr virus with leiomyosarcomas in young people with AIDS","volume":"332","author":"McClain","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/aje\/152.1.13","article-title":"Soft-tissue sarcoma and non-Hodgkin\u2019s lymphoma clusters around a municipal solid waste incinerator with high dioxin emission levels","volume":"152","author":"Viel","year":"2000","journal-title":"Am. J. Epidemiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1476-069X-6-19","article-title":"Sarcoma risk and dioxin emissions from incinerators and industrial plants: A population-based case-control study (Italy)","volume":"6","author":"Zambon","year":"2007","journal-title":"Environ. Health"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Choong, P.F.M. (2021). The Epidemiology and Pathogenesis of Sarcoma BT\u2014Sarcoma: A Practical Guide to Multidisciplinary Management, Springer.","DOI":"10.1007\/978-981-15-9414-4"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"iv51","DOI":"10.1093\/annonc\/mdy096","article-title":"Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/jso.25052","article-title":"Improved survival for extremity soft tissue sarcoma treated in high-volume facilities","volume":"117","author":"Abarca","year":"2018","journal-title":"J. Surg. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Sarcoma Meta-Analysis Collaboration (1997). Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: Meta-analysis of individual data. Lancet, 350, 1647\u20131654.","DOI":"10.1016\/S0140-6736(97)08165-8"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/cncr.23592","article-title":"A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma","volume":"113","author":"Pervaiz","year":"2008","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3322\/caac.21605","article-title":"Soft-tissue sarcoma in adults: An update on the current state of histiotype-specific management in an era of personalized medicine","volume":"70","author":"Gamboa","year":"2020","journal-title":"CA. Cancer J. Clin."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41577-019-0257-x","article-title":"B cells, plasma cells and antibody repertoires in the tumour microenvironment","volume":"20","author":"Sharonov","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Sorbye, S.W., Kilvaer, T., Valkov, A., Donnem, T., Smeland, E., Al-Shibli, K., Bremnes, R.M., and Busund, L.-T. (2011). Prognostic impact of lymphocytes in soft tissue sarcomas. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0014611"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00262-019-02322-y","article-title":"An immunosuppressive macrophage profile attenuates the prognostic impact of CD20-positive B cells in human soft tissue sarcoma","volume":"68","author":"Tsagozis","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Lee, A.T.J., Chew, W., Wilding, C.P., Guljar, N., Smith, M.J., Strauss, D.C., Fisher, C., Hayes, A.J., Judson, I., and Thway, K. (2019). The adequacy of tissue microarrays in the assessment of inter- and intra-tumoural heterogeneity of infiltrating lymphocyte burden in leiomyosarcoma. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-50888-5"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1111\/cas.14161","article-title":"Comprehensive immune characterization and T-cell receptor repertoire heterogeneity of retroperitoneal liposarcoma","volume":"110","author":"Yan","year":"2019","journal-title":"Cancer Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"9211","DOI":"10.1038\/s41598-019-45551-y","article-title":"CD163+ immune cell infiltrates and presence of CD54+ microvessels are prognostic markers for patients with embryonal rhabdomyosarcoma","volume":"9","author":"Kather","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","article-title":"B cells are associated with survival and immunotherapy response in sarcoma","volume":"577","author":"Petitprez","year":"2020","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1258\/ebm.2011.011007","article-title":"Tumor-infiltrating immune cells and prognosis: The potential link between conventional cancer therapy and immunity","volume":"236","author":"Jochems","year":"2011","journal-title":"Exp. Biol. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1038\/onc.2010.174","article-title":"Human FOXP3 and cancer","volume":"29","author":"Martin","year":"2010","journal-title":"Oncogene"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Budczies, J., Mechtersheimer, G., Denkert, C., Klauschen, F., Mughal, S.S., Chudasama, P., Bockmayr, M., J\u00f6hrens, K., Endris, V., and Lier, A. (2017). PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma. Oncoimmunology, 6.","DOI":"10.1080\/2162402X.2017.1279777"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Zhu, M.M.T., Shenasa, E., and Nielsen, T.O. (2020). Sarcomas: Immune biomarker expression and checkpoint inhibitor trials. Cancer Treat. Rev., 91.","DOI":"10.1016\/j.ctrv.2020.102115"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"387","DOI":"10.21037\/atm.2019.07.43","article-title":"Changes in the tumor immune microenvironment in resected recurrent soft tissue sarcomas","volume":"7","author":"Zheng","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"71371","DOI":"10.18632\/oncotarget.19071","article-title":"Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8(+) lymphocytes in primary sarcomas is subtype dependent","volume":"8","author":"Gorris","year":"2017","journal-title":"Oncotarget"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1111\/cas.13769","article-title":"Prognostic impact of the tumor immune microenvironment in synovial sarcoma","volume":"109","author":"Oike","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/path.2819","article-title":"Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression","volume":"223","author":"Berghuis","year":"2011","journal-title":"J. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/ijc.28581","article-title":"CD8+ tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma","volume":"134","author":"Fujii","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Klaver, Y., Rijnders, M., Oostvogels, A., Wijers, R., Smid, M., Gr\u00fcnhagen, D., Verhoef, C., Sleijfer, S., Lamers, C., and Debets, R. (2020). Differential quantities of immune checkpoint-expressing CD8 T cells in soft tissue sarcoma subtypes. J. Immunother. Cancer, 8.","DOI":"10.1136\/jitc-2019-000271"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Raj, S.K.S., Kooshki, M., Winters, M., Russell, G.B., Miller, L.D., Laurini, J.A., Pierre, T., and Savage, P.D. (2019). Prognostic implications of tumor associated macrophages (TAMs) in soft tissue sarcoma. J. Clin. Oncol., 37.","DOI":"10.1200\/JCO.2019.37.15_suppl.e22548"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2217\/imt-2017-0120","article-title":"PD-1\/PD-L1 in disease","volume":"10","author":"Kuol","year":"2018","journal-title":"Immunotherapy"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13045-018-0560-1","article-title":"PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse","volume":"11","author":"Zheng","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.pathol.2017.05.003","article-title":"PD-1 and PD-L1 expression in bone and soft tissue sarcomas","volume":"49","author":"Torabi","year":"2017","journal-title":"Pathology"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Kim, J.R., Moon, Y.J., Kwon, K.S., Bae, J.S., Wagle, S., Kim, K.M., Park, H.S., Lee, H., Moon, W.S., and Chung, M.J. (2013). Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0082870"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Kim, C., Kim, E.K., Jung, H., Chon, H.J., Han, J.W., Shin, K.-H., Hu, H., Kim, K.S., Choi, Y.D., and Kim, S. (2016). Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2451-6"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Patel, K.R., Martinez, A., Stahl, J.M., Logan, S.J., Perricone, A.J., Ferris, M.J., Buchwald, Z.S., Chowdhary, M., Delman, K.A., and Monson, D.K. (2018). Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma. Oncoimmunology, 7.","DOI":"10.1080\/2162402X.2018.1442168"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1172\/JCI21583","article-title":"Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes","volume":"114","author":"Munn","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3389\/fimmu.2020.00274","article-title":"IDO Targeting in Sarcoma: Biological and Clinical Implications","volume":"11","author":"Nafia","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Friedlaender, A., Addeo, A., and Banna, G. (2019). New emerging targets in cancer immunotherapy: The role of TIM3. ESMO Open, 4.","DOI":"10.1136\/esmoopen-2019-000497"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Solinas, C., Migliori, E., De Silva, P., and Willard-Gallo, K. (2019). LAG3: The Biological Processes That Motivate Targeting This Immune Checkpoint Molecule in Human Cancer. Cancers, 11.","DOI":"10.3390\/cancers11081213"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"331","DOI":"10.20892\/j.issn.2095-3941.2018.0306","article-title":"LAG-3 expression on tumor-infiltrating T cells in soft tissue sarcoma correlates with poor survival","volume":"16","author":"Que","year":"2019","journal-title":"Cancer Biol. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41568-019-0183-z","article-title":"Phagocytosis checkpoints as new targets for cancer immunotherapy","volume":"19","author":"Feng","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Dancsok, A.R., Gao, D., Lee, A.F., Steigen, S.E., Blay, J.-Y., Thomas, D.M., Maki, R.G., Nielsen, T.O., and Demicco, E.G. (2020). Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas. Oncoimmunology, 9.","DOI":"10.1080\/2162402X.2020.1747340"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_49","unstructured":"(2017). Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell, 171, 950\u2013965.e28."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/1724600820925095","article-title":"The landscape of gene mutations and clinical significance of tumor mutation burden in patients with soft tissue sarcoma who underwent surgical resection and received conventional adjuvant therapy","volume":"35","author":"Xu","year":"2020","journal-title":"Int. J. Biol. Markers"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.humpath.2020.04.007","article-title":"Tumor mutation burden and checkpoint immunotherapy markers in primary and metastatic synovial sarcoma","volume":"100","author":"He","year":"2020","journal-title":"Hum. Pathol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/gcc.22114","article-title":"Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas","volume":"53","author":"Joseph","year":"2014","journal-title":"Genes. Chromosomes Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1158\/1078-0432.CCR-14-2744","article-title":"Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma","volume":"21","author":"Agelopoulos","year":"2015","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/ng0294-152","article-title":"Instability of short tandem repeats (microsatellites) in human cancers","volume":"6","author":"Wooster","year":"1994","journal-title":"Nat. Genet."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1158\/1535-7163.MCT-19-0579","article-title":"Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies","volume":"19","author":"Groisberg","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.1038\/sj.onc.1210419","article-title":"Frequent alteration of DNA damage signalling and repair pathways in human colorectal cancers with microsatellite instability","volume":"26","author":"Miquel","year":"2007","journal-title":"Oncogene"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1158\/1078-0432.CCR-11-1469","article-title":"Molecular pathways: Microsatellite instability in colorectal cancer: Prognostic, predictive, and therapeutic implications","volume":"18","author":"Sinicrope","year":"2012","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_59","unstructured":"Ruci\u0144ska, M., Koz\u0142owski, L., Pepi\u0144ski, W., Skawro\u0144ska, M., Janica, J., and Wojtukiewic, M.Z. (2005). High grade sarcomas are associated with microsatellite instability (chromosom 12) and loss of heterozygosity (chromosom 2). Med. Sci. Monit. Int. Med. J. Exp. Clin. Res., 11."},{"key":"ref_60","first-page":"241","article-title":"Microsatellite instability and hMLH1 and hMSH2 expression analysis in soft tissue sarcomas","volume":"13","author":"Kawaguchi","year":"2005","journal-title":"Oncol. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000369906","article-title":"Absence of Microsatellite Instability in Soft Tissue Sarcomas","volume":"82","author":"Campanella","year":"2015","journal-title":"Pathobiology"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Ranjan, A., and Iwakuma, T. (2016). Non-Canonical Cell Death Induced by p53. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17122068"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3389\/fonc.2015.00288","article-title":"Targeting Oncogenic Mutant p53 for Cancer Therapy","volume":"5","author":"Parrales","year":"2015","journal-title":"Front. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/362857a0","article-title":"Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53","volume":"362","author":"Oliner","year":"1993","journal-title":"Nature"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.path.2016.04.009","article-title":"Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma","volume":"9","year":"2016","journal-title":"Surg. Pathol. Clin."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/cncr.26390","article-title":"Sarcomas in TP53 germline mutation carriers: A review of the IARC TP53 database","volume":"118","author":"Ognjanovic","year":"2012","journal-title":"Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/hmg\/10.7.699","article-title":"The Rb\/E2F pathway and cancer","volume":"10","author":"Nevins","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/2045-3329-2-15","article-title":"Sarcomas in hereditary retinoblastoma","volume":"2","author":"Kleinerman","year":"2012","journal-title":"Clin. Sarcoma Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/B978-0-444-52891-9.00039-7","article-title":"Neurofibromatosis","volume":"111","author":"Korf","year":"2013","journal-title":"Handb. Clin. Neurol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(09)70033-6","article-title":"Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1","volume":"10","author":"Brems","year":"2009","journal-title":"Lancet. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrclinonc.2013.10","article-title":"Development of PI3K inhibitors: Lessons learned from early clinical trials","volume":"10","author":"Rodon","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"12234","DOI":"10.18632\/oncotarget.3498","article-title":"Multi-platform profiling of over 2000 sarcomas: Identification of biomarkers and novel therapeutic targets","volume":"6","author":"Movva","year":"2015","journal-title":"Oncotarget"},{"key":"ref_73","first-page":"457","article-title":"Mutational analysis of p53 and PTEN in soft tissue sarcoma","volume":"5","author":"Yin","year":"2012","journal-title":"Mol. Med. Rep."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0002-9440(10)65504-6","article-title":"Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas","volume":"155","author":"Kourea","year":"1999","journal-title":"Am. J. Pathol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/(SICI)1098-2264(199910)26:2<151::AID-GCC7>3.0.CO;2-A","article-title":"Chromosome band 9p21 is frequently altered in malignant peripheral nerve sheath tumors: Studies of CDKN2A and other genes of the pRB pathway","volume":"26","author":"Berner","year":"1999","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1158\/0008-5472.CAN-04-3050","article-title":"SMARCB1\/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas","volume":"65","author":"Modena","year":"2005","journal-title":"Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"6936","DOI":"10.1158\/0008-5472.CAN-05-4578","article-title":"Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas","volume":"66","author":"Davicioni","year":"2006","journal-title":"Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Romualdi, C., De Pitt\u00e0, C., Tombolan, L., Bortoluzzi, S., Sartori, F., Rosolen, A., and Lanfranchi, G. (2006). Defining the gene expression signature of rhabdomyosarcoma by meta-analysis. BMC Genom., 7.","DOI":"10.1186\/1471-2164-7-287"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-018-0051-2","article-title":"Rhabdomyosarcoma","volume":"5","author":"Skapek","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(02)08270-3","article-title":"Molecular characterisation of soft tissue tumours: A gene expression study","volume":"359","author":"Nielsen","year":"2002","journal-title":"Lancet"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0002-9440(10)64437-9","article-title":"Expression profiling of synovial sarcoma by cDNA microarrays: Association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation","volume":"161","author":"Allander","year":"2002","journal-title":"Am. J. Pathol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/gcc.1155","article-title":"Clinical impact of molecular and cytogenetic findings in synovial sarcoma","volume":"31","author":"Panagopoulos","year":"2001","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_83","first-page":"5108","article-title":"Fusion of PAX3 to a Member of the Forkhead Family of Transcription Factors in Human Alveolar Rhabdomyosarcoma","volume":"53","author":"Shapiro","year":"1993","journal-title":"Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1200\/JCO.2002.03.137","article-title":"Barr, alveolar rhabdomyosarcoma: A report from F.G. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in the children\u2019s oncology group","volume":"20","author":"Sorensen","year":"2002","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"13126","DOI":"10.1073\/pnas.1612734113","article-title":"Fusion transcriptome profiling provides insights into alveolar rhabdomyosarcoma","volume":"113","author":"Xie","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1080\/15476286.2018.1564464","article-title":"PAX3-FOXO1 escapes miR-495 regulation during muscle differentiation","volume":"16","author":"Xie","year":"2019","journal-title":"RNA Biol."},{"key":"ref_87","unstructured":"Pollock, R.E. (2002). Experimental Approaches, BC Decker."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.humpath.2014.04.012","article-title":"Molecular profiling of soft tissue sarcomas using next-generation sequencing: A pilot study toward precision therapeutics","volume":"45","author":"Jour","year":"2014","journal-title":"Hum. Pathol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"5659","DOI":"10.1158\/0008-5472.CAN-11-0890","article-title":"Small RNA sequencing and functional characterization reveals MicroRNA-143 tumor suppressor activity in liposarcoma","volume":"71","author":"Ugras","year":"2011","journal-title":"Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/gcc.21980","article-title":"MicroRNA profiling of primary high-grade soft tissue sarcomas","volume":"51","author":"Renner","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1158\/2159-8290.CD-11-0181","article-title":"Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas","volume":"1","author":"Taylor","year":"2011","journal-title":"Cancer Discov."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3233\/CBM-170496","article-title":"Whole blood miRNA expression analysis reveals miR-3613-3p as a potential biomarker for dedifferentiated liposarcoma","volume":"22","author":"Fricke","year":"2018","journal-title":"Cancer Biomark."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1158\/0008-5472.CAN-11-3027","article-title":"MiR-155 is a liposarcoma oncogene that targets casein kinase-1\u03b1 and enhances \u03b2-catenin signaling","volume":"72","author":"Zhang","year":"2012","journal-title":"Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.bbrc.2012.09.063","article-title":"TLS-CHOP represses miR-486 expression, inducing upregulation of a metastasis regulator PAI-1 in human myxoid liposarcoma","volume":"427","author":"Borjigin","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Lee, D.H., Amanat, S., Goff, C., Weiss, L.M., Said, J.W., Doan, N.B., Sato-Otsubo, A., Ogawa, S., Forscher, C., and Koeffler, H.P. (2013). Overexpression of miR-26a-2 in human liposarcoma is correlated with poor patient survival. Oncogenesis, 2.","DOI":"10.1038\/oncsis.2013.10"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4161\/cc.8.1.7292","article-title":"Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma","volume":"8","author":"Ciarapica","year":"2009","journal-title":"Cell Cycle"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1038\/sj.onc.1210836","article-title":"MicroRNA expression signature of human sarcomas","volume":"27","author":"Subramanian","year":"2008","journal-title":"Oncogene"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/sj.bjc.6605684","article-title":"MicroRNA-206 expression levels correlate with clinical behaviour of rhabdomyosarcomas","volume":"102","author":"Missiaglia","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1016\/j.yexcr.2012.07.015","article-title":"Differential expression of miRNAs in rhabdomyosarcoma and malignant rhabdoid tumor","volume":"318","author":"Herrmann","year":"2012","journal-title":"Exp. Cell Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/labinvest.2012.10","article-title":"Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma","volume":"92","author":"Li","year":"2012","journal-title":"Lab. Investig."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1158\/1078-0432.CCR-10-0091","article-title":"Genomic and clinical analysis of amplification of the 13q31 chromosomal region in alveolar rhabdomyosarcoma: A report from the Children\u2019s Oncology Group","volume":"17","author":"Reichek","year":"2011","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1124\/mol.110.069633","article-title":"Novel regulation of nuclear factor-YB by miR-485-3p affects the expression of DNA topoisomerase II\u03b1 and drug responsiveness","volume":"79","author":"Chen","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbrc.2010.08.015","article-title":"Circulating muscle-specific microRNA, miR-206, as a potential diagnostic marker for rhabdomyosarcoma","volume":"400","author":"Miyachi","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/path.2633","article-title":"Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours","volume":"220","author":"Subramanian","year":"2010","journal-title":"J. Pathol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/PDM.0b013e31815aca19","article-title":"Benign metastasizing leiomyoma of the lung: Clinicopathologic, immunohistochemical, and micro-RNA analyses","volume":"17","author":"Nuovo","year":"2008","journal-title":"Diagn. Mol. Pathol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/gcc.22179","article-title":"Differentiating soft tissue leiomyosarcoma and undifferentiated pleomorphic sarcoma: A miRNA analysis","volume":"53","author":"Guled","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/labinvest.2010.53","article-title":"S-MED: Sarcoma microRNA expression database","volume":"90","author":"Sarver","year":"2010","journal-title":"Lab. Invest."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12943-015-0424-z","article-title":"Identification of a blood-borne miRNA signature of synovial sarcoma","volume":"14","author":"Fricke","year":"2015","journal-title":"Mol. Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/bjc.2012.518","article-title":"MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression","volume":"108","author":"Presneau","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/nar\/gkn920","article-title":"Twist-1 regulates the miR-199a\/214 cluster during development","volume":"37","author":"Lee","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/neuonc\/nos124","article-title":"MicroRNA-204 critically regulates carcinogenesis in malignant peripheral nerve sheath tumors","volume":"14","author":"Gong","year":"2012","journal-title":"Neuro-Oncology"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/path.4294","article-title":"EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell survival and tumourigenesis","volume":"232","author":"Zhang","year":"2014","journal-title":"J. Pathol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/gcc.21943","article-title":"The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification","volume":"51","author":"Italiano","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4068\/cmj.2017.53.2.161","article-title":"MicroRNA-29 Family Suppresses the Invasion of HT1080 Human Fibrosarcoma Cells by Regulating Matrix Metalloproteinase 2 Expression","volume":"53","author":"Kim","year":"2017","journal-title":"Chonnam Med. J."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/jcp.22993","article-title":"miR-520c and miR-373 upregulate MMP9 expression by targeting mTOR and SIRT1, and activate the Ras\/Raf\/MEK\/Erk signaling pathway and NF-\u03baB factor in human fibrosarcoma cells","volume":"227","author":"Liu","year":"2012","journal-title":"J. Cell. Physiol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"39127","DOI":"10.18632\/oncotarget.3926","article-title":"Prognostic microRNAs modulate the RHO adhesion pathway: A potential therapeutic target in undifferentiated pleomorphic sarcomas","volume":"6","author":"Wong","year":"2015","journal-title":"Oncotarget"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/gcc.22128","article-title":"SMARCB1 expression in epithelioid sarcoma is regulated by miR-206, miR-381, and miR-671-5p on Both mRNA and protein levels","volume":"53","author":"Papp","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"5938","DOI":"10.1182\/blood-2008-09-179168","article-title":"Tumor suppressor microRNAs are underrepresented in primary effusion lymphoma and Kaposi sarcoma","volume":"113","author":"Wang","year":"2009","journal-title":"Blood"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1182\/blood-2011-01-330589","article-title":"The manipulation of miRNA-gene regulatory networks by KSHV induces endothelial cell motility","volume":"118","author":"Wu","year":"2011","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"O\u2019Hara, A.J., Chugh, P., Wang, L., Netto, E.M., Luz, E., Harrington, W.J., Dezube, B.J., Damania, B., and Dittmer, D.P. (2009). Pre-Micro RNA Signatures Delineate Stages of Endothelial Cell Transformation in Kaposi Sarcoma. PLoS Pathog., 5.","DOI":"10.1371\/journal.ppat.1000389"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ijc.26109","article-title":"Expression of microRNA 210 associates with poor survival and age of tumor onset of soft-tissue sarcoma patients","volume":"130","author":"Greither","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Bao, X., Ren, T., Huang, Y., Sun, K., Wang, S., Liu, K., Zheng, B., and Guo, W. (2017). Knockdown of long non-coding RNA HOTAIR increases miR-454-3p by targeting Stat3 and Atg12 to inhibit chondrosarcoma growth. Cell Death Dis., 8.","DOI":"10.1038\/cddis.2017.31"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"13971","DOI":"10.18632\/oncotarget.14814","article-title":"A novel long noncoding RNA PILRLS promote proliferation through TCL1A by activing MDM2 in Retroperitoneal liposarcoma","volume":"8","author":"Shao","year":"2017","journal-title":"Oncotarget"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"80336","DOI":"10.18632\/oncotarget.18165","article-title":"Prediction of clinical outcome and survival in soft-tissue sarcoma using a ten-lncRNA signature","volume":"8","author":"He","year":"2017","journal-title":"Oncotarget"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/ng.3781","article-title":"Systematic analysis of telomere length and somatic alterations in 31 cancer types","volume":"49","author":"Barthel","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1756-9966-33-33","article-title":"TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities","volume":"33","author":"Koelsche","year":"2014","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11060-014-1553-8","article-title":"TERT promoter mutations and BRAF mutations are rare in sporadic, and TERT promoter mutations are absent in NF1-related malignant peripheral nerve sheath tumors","volume":"120","author":"Dubbink","year":"2014","journal-title":"J. Neuro Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"57726","DOI":"10.18632\/oncotarget.10639","article-title":"A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: A retrospective cohort study","volume":"7","author":"Lipman","year":"2016","journal-title":"Oncotarget"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"393","DOI":"10.5858\/2000-124-0393-EOTAAT","article-title":"Expression of telomerase activity and telomerase RNA in human soft tissue sarcomas","volume":"124","author":"Yoo","year":"2000","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/nm1197-1271","article-title":"Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines","volume":"3","author":"Bryan","year":"1997","journal-title":"Nat. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"8918","DOI":"10.1158\/0008-5472.CAN-06-0273","article-title":"Telomere maintenance mechanisms in liposarcomas: Association with histologic subtypes and disease progression","volume":"66","author":"Costa","year":"2006","journal-title":"Cancer Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1158\/1078-0432.217.11.1","article-title":"A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas","volume":"11","author":"Henson","year":"2005","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.ajpath.2011.06.018","article-title":"Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes","volume":"179","author":"Heaphy","year":"2011","journal-title":"Am. J. Pathol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.humpath.2015.05.019","article-title":"Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas","volume":"46","author":"Liau","year":"2015","journal-title":"Hum. Pathol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/PAS.0000000000000324","article-title":"Leiomyosarcoma with alternative lengthening of telomeres is associated with aggressive histologic features, loss of ATRX expression, and poor clinical outcome","volume":"39","author":"Liau","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ccell.2019.02.002","article-title":"Undifferentiated Sarcomas Develop through Distinct Evolutionary Pathways","volume":"35","author":"Steele","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Miolo, G., Di Gregorio, E., Saorin, A., Lombardi, D., Scalone, S., Buonadonna, A., Steffan, A., and Corona, G. (2020). Integration of serum metabolomics into clinical assessment to improve outcome prediction of metastatic soft tissue sarcoma patients treated with trabectedin. Cancers, 12.","DOI":"10.3390\/cancers12071983"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Kowalczyk, T., Ciborowski, M., Kisluk, J., Kretowski, A., and Barbas, C. (2020). Mass spectrometry based proteomics and metabolomics in personalized oncology. Biochim. Biophys. Acta Mol. Basis Dis., 1866.","DOI":"10.1016\/j.bbadis.2020.165690"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1152\/physrev.00035.2018","article-title":"Metabolomics for investigating physiological and pathophysiological processes","volume":"99","author":"Wishart","year":"2019","journal-title":"Physiol. Rev."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1002\/jcp.24003","article-title":"Pharmaco-metabolomics: An emerging \u201comics\u201d tool for the personalization of anticancer treatments and identification of new valuable therapeutic targets","volume":"227","author":"Corona","year":"2012","journal-title":"J. Cell. Physiol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"D608","DOI":"10.1093\/nar\/gkx1089","article-title":"HMDB 4.0: The human metabolome database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"D402","DOI":"10.1093\/nar\/gkm957","article-title":"BioMagResBank","volume":"36","author":"Ulrich","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"ref_143","unstructured":"SDBS (2021, May 14). Spectral Database for Organic Compounds. Available online: https:\/\/sdbs.db.aist.go.jp\/sdbs\/cgi-bin\/cre_index.cgi."},{"key":"ref_144","unstructured":"Chenomx (2021, May 14). Chenomx NMR Suite 7.0 (Chenomx, Edmonton, Canada). Available online: https:\/\/www.chenomx.com\/."},{"key":"ref_145","unstructured":"BBIOREFCODE (2021, May 14). Metabolite Reference Database. Available online: https:\/\/www.bruker.com\/en\/products-and-solutions\/mr\/nmr-clinical-research-solutions\/bbiorefcode.html."},{"key":"ref_146","unstructured":"MetaboBase (2021, May 14). Bruker MetatoBase Personal Lybrary. Available online: https:\/\/bruker-labscape.store\/products\/bruker-metabobase-personal-library-3-0."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.csbj.2016.02.005","article-title":"A guide to the identification of metabolites in NMR-based metabonomics\/metabolomics experiments","volume":"14","author":"Dona","year":"2016","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Huang, X., Powers, R., Tymiak, A., Espina, R., and Roongta, V. (2007). Introduction to NMR and Its Application in Metabolite Structure Determination. Drug Metabolism in Drug Design and Development, John Wiley & Sons, Inc.","DOI":"10.1002\/9780470191699.ch12"},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Bitchagno, G.T.M., and Fobofou Tanemossu, S.A. (2019). Computational methods for NMR and MS for structure elucidation III: More advanced approaches. Phys. Sci. Rev., 4.","DOI":"10.1515\/psr-2018-0109"},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Boiteau, R.M., Hoyt, D.W., Nicora, C.D., Kinmonth-Schultz, H.A., Ward, J.K., and Bingol, K. (2018). Structure elucidation of unknown metabolites in metabolomics by combined NMR and MS\/MS prediction. Metabolites, 8.","DOI":"10.3390\/metabo8010008"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s13361-016-1544-4","article-title":"Prognostic Metabolite Biomarkers for Soft Tissue Sarcomas Discovered by Mass Spectrometry Imaging","volume":"28","author":"Lou","year":"2017","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1007\/s13361-016-1469-y","article-title":"Untargeted Metabolomics Strategies\u2014Challenges and Emerging Directions","volume":"27","author":"Codreanu","year":"2016","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"ref_153","unstructured":"(2021, May 14). MetaboLights. Available online: https:\/\/www.ebi.ac.uk\/metabolights\/."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.2217\/bmm-2018-0229","article-title":"Discovering biomarkers in bladder cancer by metabolomics","volume":"12","author":"Zhang","year":"2018","journal-title":"Biomark. Med."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Corona, G., Cannizzaro, R., Miolo, G., Caggiari, L., De Zorzi, M., Repetto, O., Steffan, A., and De Re, V. (2018). Use of metabolomics as a complementary omic approach to implement risk criteria for first-degree relatives of gastric cancer patients. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19030750"},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Vignoli, A., Muraro, E., Miolo, G., Tenori, L., Turano, P., Di Gregorio, E., Steffan, A., Luchinat, C., and Corona, G. (2020). Effect of estrogen receptor status on circulatory immune and metabolomics profiles of her2-positive breast cancer patients enrolled for neoadjuvant targeted chemotherapy. Cancers, 12.","DOI":"10.3390\/cancers12020314"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12020-019-01904-1","article-title":"Advances in metabolomics of thyroid cancer diagnosis and metabolic regulation","volume":"65","author":"Abooshahab","year":"2019","journal-title":"Endocrine"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1194\/jlr.M088559","article-title":"Global analysis of osteosarcoma lipidomes reveal altered lipid profiles in metastatic versus nonmetastatic cells","volume":"60","author":"Roy","year":"2019","journal-title":"J. Lipid Res."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Kelly, A.D., Breitkopf, S.B., Yuan, M., Goldsmith, J., Spentzos, D., and Asara, J.M. (2011). Metabolomic profiling from formalin-fixed, paraffin-embedded tumor tissue using targeted LC\/MS\/MS: Application in sarcoma. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0025357"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1158\/2159-8290.CD-12-0197","article-title":"Metabolomics strategy reveals subpopulation of liposarcomas sensitive to gemcitabine treatment","volume":"2","author":"Braas","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_161","first-page":"1","article-title":"Targeting glutamine metabolism slows soft tissue sarcoma growth","volume":"11","author":"Lee","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.cmet.2011.12.009","article-title":"Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in b cells","volume":"15","author":"Le","year":"2012","journal-title":"Cell Metab."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature12040","article-title":"Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway","volume":"496","author":"Son","year":"2013","journal-title":"Nature"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2015.07.016","article-title":"An Essential Role of the Mitochondrial Electron Transport Chain in Cell Proliferation Is to Enable Aspartate Synthesis","volume":"162","author":"Birsoy","year":"2015","journal-title":"Cell"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.cell.2015.07.017","article-title":"Supporting Aspartate Biosynthesis Is an Essential Function of Respiration in Proliferating Cells","volume":"162","author":"Sullivan","year":"2015","journal-title":"Cell"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1038\/ncb3272","article-title":"Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma","volume":"17","author":"Tardito","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/MCO.0b013e32829fb38d","article-title":"Citrulline and the gut","volume":"10","author":"Curis","year":"2007","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/1724600818817316","article-title":"The metabolomic scent of cancer disease progression in soft tissue sarcoma: A case report","volume":"34","author":"Miolo","year":"2019","journal-title":"Int. J. Biol. Markers"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1007\/s12094-020-02494-5","article-title":"The free amino acid profiles and metabolic biomarkers of predicting the chemotherapeutic response in advanced sarcoma patients","volume":"22","author":"Jia","year":"2020","journal-title":"Clin. Transl. Oncol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"251","DOI":"10.4143\/crt.2013.45.4.251","article-title":"Targeting arginine-dependent cancers with arginine-degrading enzymes: Opportunities and challenges","volume":"45","author":"Phillips","year":"2013","journal-title":"Cancer Res. Treat."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1021\/pr100480r","article-title":"Serum and urinary metabonomic study of human osteosarcoma","volume":"9","author":"Zhang","year":"2010","journal-title":"J. Proteome Res."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/mrc.4925","article-title":"Metabolic profiling of serum in patients with cartilage tumours using 1H-NMR spectroscopy: A pilot study","volume":"58","year":"2020","journal-title":"Magn. Reson. Chem."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41698-021-00157-4","article-title":"Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas","volume":"5","author":"Merry","year":"2021","journal-title":"Jnp. Precis. Oncol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10555-016-9630-4","article-title":"The roles and implications of exosomes in sarcoma","volume":"35","author":"Min","year":"2016","journal-title":"Cancer Metastasis Rev."},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Gr\u00fcnewald, T.G.P., Alonso, M., Avnet, S., Banito, A., Burdach, S., Cidre-Aranaz, F., Di Pompo, G., Distel, M., Dorado-Garcia, H., and Garcia-Castro, J. (2020). Sarcoma treatment in the era of molecular medicine. EMBO Mol. Med., 12.","DOI":"10.15252\/emmm.201911131"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.2147\/OTT.S62349","article-title":"Isolation, detection, and immunomorphological characterization of circulating tumor cells (CTCs) from patients with different types of sarcoma using isolation by size of tumor cells: A window on sarcoma-cell invasion","volume":"7","author":"Chinen","year":"2014","journal-title":"OncoTargets Ther."},{"key":"ref_177","first-page":"202","article-title":"The Challenges of Detecting Circulating Tumor Cells in Sarcoma","volume":"6","author":"Brown","year":"2016","journal-title":"Front. Oncol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1158\/1535-7163.MCT-20-0441","article-title":"Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma","volume":"20","author":"Pousa","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3389\/fchem.2020.00143","article-title":"The Translational Potential of Electrochemical DNA-Based Liquid Biopsy","volume":"8","author":"Palchetti","year":"2020","journal-title":"Front. Chem."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"106929","DOI":"10.1016\/j.elecom.2021.106929","article-title":"Electrochemical and PEC platforms for miRNA and other epigenetic markers of cancer diseases: Recent updates","volume":"124","author":"Sfragano","year":"2021","journal-title":"Electrochem. Commun."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.bios.2016.09.058","article-title":"Direct determination of small RNAs using a biotinylated polythiophene impedimetric genosensor","volume":"87","author":"Voccia","year":"2017","journal-title":"Biosens. Bioelectron."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/14737140.2020.1708198","article-title":"Individualizing systemic therapy for advanced soft tissue sarcomas based on tumor histology and biology","volume":"20","author":"Haddox","year":"2020","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/1878-0261.12522","article-title":"PARP1 expression in soft tissue sarcomas is a poor-prognosis factor and a new potential therapeutic target","volume":"13","author":"Bertucci","year":"2019","journal-title":"Mol. Oncol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1470-2045(19)30153-6","article-title":"Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: A single-centre, single-arm, phase 2 trial","volume":"20","author":"Wilky","year":"2019","journal-title":"Lancet. Oncol."},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Van Tine, B., Butler, M., Araujo, D., Johnson, M., Clarke, J., Liebner, D., Odunsi, K., Olszanski, A., Basu, S., and Brophy, F. (2019). 1670OADP-A2M4 (MAGE-A4) in patients with synovial sarcoma. Ann. Oncol., 30.","DOI":"10.1093\/annonc\/mdz283.003"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S1470-2045(18)30438-8","article-title":"Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): An open-label, phase 1b study from the Italian Sarcoma Group","volume":"19","author":"Grignani","year":"2018","journal-title":"Lancet. Oncol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12943-017-0652-5","article-title":"PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models","volume":"16","author":"Pignochino","year":"2017","journal-title":"Mol. Cancer"},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Stacchiotti, S., Schoffski, P., Jones, R., Agulnik, M., Villalobos, V.M., Jahan, T.M., Chen, T.W.-W., Italiano, A., Demetri, G.D., and Cote, G.M. (2019). Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950). J. Clin. Oncol., 37.","DOI":"10.1200\/JCO.2019.37.15_suppl.11003"},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Wagner, A.J., Ravi, V., Ganjoo, K.N., Van Tine, B.A., Riedel, R.F., Chugh, R., Cranmer, L.D., Gordon, E.M., Hornick, J.L., and Kwiatkowski, D.J. (2019). ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open label phase II registration trial. J. Clin. Oncol., 37.","DOI":"10.1200\/JCO.2019.37.15_suppl.11005"},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Dickson, M.A., Koff, A., D\u2019Angelo, S.P., Gounder, M.M., Keohan, M.L., Kelly, C.M., Chi, P., Antonescu, C.R., Landa, J., and Qin, L.-X. (2019). Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma. J. Clin. Oncol., 37.","DOI":"10.1200\/JCO.2019.37.15_suppl.11004"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"39254","DOI":"10.18632\/oncotarget.16845","article-title":"Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas","volume":"8","author":"Groisberg","year":"2017","journal-title":"Oncotarget"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1001\/jamaoncol.2018.0723","article-title":"Targetable Alterations in Adult Patients with Soft-Tissue Sarcomas: Insights for Personalized Therapy","volume":"4","author":"Lucchesi","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/12\/3044\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:18:27Z","timestamp":1760163507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/12\/3044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,18]]},"references-count":193,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["cancers13123044"],"URL":"https:\/\/doi.org\/10.3390\/cancers13123044","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,18]]}}}